Raia Drogasil S.A. (RADLY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Raia Drogasil S.A. (RADLY) trades at $3.54 with AI Score 49/100 (Grade C). Raia Drogasil S. A. is a leading Brazilian retailer in the pharmaceutical sector, operating over 2,500 drugstores across the country. Market cap: $6.18B, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026RADLY stock analysis for 2026: Analysts have set a consensus price target of $5.40 for Raia Drogasil S.A., suggesting 52.8% upside from the current price of $3.54. The AI MoonshotScore is 49/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
RADLY: the 1 perspectives are evenly split.
How is this calculated? →Raia Drogasil S.A. (RADLY) Healthcare & Pipeline Overview
Raia Drogasil S.A. is a prominent player in Brazil's pharmaceutical retail sector, with a robust network of over 2,500 stores and a diverse product offering that includes medicines, cosmetics, and personal care items, catering to a wide range of consumer needs.
What Is the Investment Thesis for RADLY?
Raia Drogasil S.A. presents a compelling investment thesis driven by its strong market position and consistent growth metrics. With a market capitalization of $6.18B and a P/E ratio of 21.1, the company demonstrates solid profitability, reflected in its profit margin of 2.9% and gross margin of 27.8%. The ongoing expansion of its drugstore network and the introduction of new product lines are expected to drive revenue growth. Additionally, the company's low beta of 0.11 indicates lower volatility compared to the broader market, appealing to risk-averse investors. The dividend yield of 2.31% further enhances its attractiveness as a stable income-generating asset. However, investors may want to evaluate potential risks, including regulatory changes in the healthcare sector and competition from both local and international players.
Based on FMP financials and quantitative analysis
RADLY Key Highlights
- Market Cap of $6.18B indicates a strong presence in the Brazilian pharmaceutical retail market.
- P/E ratio of 21.1 suggests a premium valuation compared to peers, reflecting investor confidence.
- Profit margin of 2.9% and gross margin of 27.8% highlight effective cost management and operational efficiency.
- Beta of 0.11 indicates lower stock volatility, appealing to conservative investors.
- Dividend yield of 2.31% provides a steady income stream for shareholders.
Who Are RADLY's Competitors?
RADLY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MSMKF MatsukiyoCocokara & Co. | $14.60 | +0.00% | $5.74B | 49 |
| GNGBY Getinge AB (publ) | $21.24 | +0.80% | $5.78B | 47 |
| SHPMY Shanghai Pharmaceuticals Holding Co., Ltd | $7.60 | +3.54% | $5.64B | 40 |
| CNVVY ConvaTec Group Plc | $11.74 | +0.41% | $5.74B | 43 |
| DSRLF DiaSorin S.p.A. | $84.10 | +13.27% | $4.16B | 52 |
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RADLY's Key Strengths?
- Strong market presence with over 2,500 stores.
- Diverse product portfolio catering to various consumer needs.
- Established brand with high consumer trust.
- Efficient operational management leading to stable profit margins.
What Are RADLY's Weaknesses?
- Dependence on the Brazilian market for revenue.
- Relatively low profit margin compared to industry leaders.
- Limited international presence compared to global competitors.
- Potential vulnerability to regulatory changes in the healthcare sector.
What Could Drive RADLY Stock Higher?
- Expansion of store network with plans to open new locations in underserved areas of Brazil.
- Continued growth in e-commerce sales as the company enhances its online platform.
- Diversification of product offerings to include more specialty medicines and health products.
- Strategic partnerships with healthcare providers to create integrated health solutions.
- Focus on improving customer experience through enhanced in-store services and technology.
What Are the Key Risks for RADLY?
- Regulatory changes impacting the pharmaceutical retail sector.
- Intense competition from both local and international pharmacy chains.
- Economic fluctuations affecting consumer spending on healthcare products.
- Supply chain disruptions that could impact product availability.
- Currency risk associated with fluctuations in the Brazilian real.
What Are the Growth Opportunities for RADLY?
- Expansion of Store Network: Raia Drogasil plans to increase its footprint by opening new drugstores in underserved regions of Brazil. The Brazilian pharmacy market is projected to grow at a CAGR of 10% over the next five years, providing a significant opportunity for Raia Drogasil to capture additional market share and enhance its revenue streams.
- E-commerce Growth: With the rise of online shopping, Raia Drogasil is investing in its e-commerce platform to reach a broader customer base. The online pharmaceutical market in Brazil is expected to grow by 20% annually, allowing the company to tap into a growing segment of tech-savvy consumers seeking convenient access to health products.
- Diversification of Product Offerings: The company is expanding its range of specialty medicines and health-related products, targeting specific consumer needs. This strategy aligns with the increasing consumer demand for personalized healthcare solutions, expected to drive sales growth in the specialty segment by approximately 15% over the next few years.
- Strategic Partnerships: Raia Drogasil is exploring partnerships with healthcare providers and insurance companies to offer integrated health solutions. This approach is anticipated to enhance customer loyalty and increase foot traffic to its stores, contributing to a projected revenue growth of 8% annually.
- Focus on Customer Experience: By enhancing in-store experiences and leveraging technology for better customer engagement, Raia Drogasil aims to improve customer retention rates. The emphasis on customer service is expected to yield a 5% increase in repeat purchases over the next year.
What Opportunities Does RADLY Have?
- Expansion into underserved regions of Brazil.
- Growth in e-commerce sales for health products.
- Increasing demand for specialty medicines.
- Strategic partnerships with healthcare providers.
What Threats Does RADLY Face?
- Intense competition from both local and international players.
- Regulatory risks affecting the pharmaceutical industry.
- Economic fluctuations impacting consumer spending.
- Potential supply chain disruptions in the healthcare sector.
What Are RADLY's Competitive Advantages?
- Established brand recognition and trust among Brazilian consumers.
- Extensive network of drugstores providing convenient access to products.
- Diverse product offerings catering to a wide range of consumer needs.
- Strong customer service through telesales and call centers.
- Strategic location of stores in high-traffic areas enhancing visibility.
What Does RADLY Do?
Founded in 1905, Raia Drogasil S.A. has evolved into one of Brazil's largest pharmacy chains, with a mission to provide accessible healthcare products to the population. Headquartered in São Paulo, the company operates a vast network of 2,530 drugstores across 26 Brazilian states. Over the years, Raia Drogasil has expanded its offerings beyond traditional pharmaceuticals to include perfumery, personal care, beauty products, cosmetics, dermocosmetics, and specialty medicines. This diversification has enabled the company to cater to a broad customer base, enhancing its market presence. Raia Drogasil also utilizes modern marketing strategies, including telesales and call centers located in São Paulo, Tocantins, and Pernambuco, to reach customers effectively. The company's commitment to quality and customer service has solidified its reputation in the Brazilian healthcare sector, making it a trusted choice for consumers seeking a variety of health and wellness products.
What Products and Services Does RADLY Offer?
- Retail sale of medicines and pharmaceuticals in Brazil.
- Offer a wide range of personal care and beauty products.
- Provide cosmetics and dermocosmetics for skincare.
- Market specialty medicines for chronic and complex conditions.
- Utilize telesales and call centers for customer outreach.
- Operate a network of over 2,500 drugstores across 26 states.
How Does RADLY Make Money?
- Generate revenue through the retail sale of pharmaceuticals and health-related products.
- Leverage a vast network of physical stores to reach consumers directly.
- Utilize e-commerce platforms to expand sales channels and customer reach.
- Implement telesales and call center services to enhance customer service and sales.
- Diversify product offerings to cater to various consumer needs and preferences.
What Industry Does RADLY Operate In?
The pharmaceutical retail industry in Brazil is characterized by a growing demand for healthcare products, driven by an aging population and increasing health awareness among consumers. The market is expected to expand as more individuals seek convenient access to medications and personal care products. Raia Drogasil S.A. is well-positioned within this competitive landscape, facing rivals such as MatsukiyoCocokara & Co. (MSMKF), Getinge AB (publ) (GNGBY), and Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY). The overall pharmaceutical market in Brazil is projected to grow significantly, providing ample opportunities for established players like Raia Drogasil to capture market share and enhance profitability.
Who Are RADLY's Key Customers?
- General public seeking over-the-counter and prescription medications.
- Consumers interested in personal care and beauty products.
- Patients requiring specialty medicines for chronic conditions.
- Health-conscious individuals looking for dermocosmetics and skincare solutions.
- Online shoppers seeking convenience in purchasing health products.
RADLY Valuation & Market Position
With a $6.18B market cap, Raia Drogasil S.A. sits in the mid-cap segment of the market. Relative to its peer group, RADLY's quantitative score of 49/100 is roughly in line with the peer average of 46/100.
FY2026 estForward Outlook
Wall Street analysts project Raia Drogasil S.A. revenue of about $48.03B for fiscal 2026, with EPS near $0.94. The estimate reflects 5 contributing analysts.
F-Score 7/9Financial Health
Raia Drogasil S.A.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.36 places it in the safe zone, indicating low near-term bankruptcy risk.
ROE 18%Key Financial Metrics
Return on equity for Raia Drogasil S.A. stands at 18.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.1%, showing how much profit it generates from its asset base. RADLY trades at a trailing price-to-earnings ratio of 21.11, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.7%, the inverse of the P/E and a quick read on earnings relative to price.
RADLY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market presence with over 2,500 stores.
- Diverse product portfolio catering to various consumer needs.
- Established brand with high consumer trust.
- Efficient operational management leading to stable profit margins.
Bear Case
- Dependence on the Brazilian market for revenue.
- Relatively low profit margin compared to industry leaders.
- Limited international presence compared to global competitors.
- Potential vulnerability to regulatory changes in the healthcare sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RADLY Latest News
No recent news available for RADLY.
RADLY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RADLY.
Price Targets
Consensus target: $5.40
RADLY MoonshotScore
What does this score mean?
The MoonshotScore rates RADLY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Renato Cepollina Raduan
CEO
Renato Cepollina Raduan has extensive experience in the retail and healthcare sectors. He has held various leadership roles, focusing on operational excellence and strategic growth. Raduan holds a degree in Business Administration and has been pivotal in driving Raia Drogasil's expansion and market positioning.
Track Record: Under Raduan's leadership, Raia Drogasil has significantly expanded its store network and diversified its product offerings, resulting in consistent revenue growth. His strategic initiatives have strengthened the company's market position in Brazil's competitive pharmaceutical landscape.
Raia Drogasil S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) allows U.S. investors to buy shares in foreign companies like Raia Drogasil S.A. Each ADR represents a specific number of shares in the underlying company, facilitating easier investment in international markets.
- Home Market Ticker: RADL, Brazil
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: RADL
RADLY OTC Market Information
The OTC Other tier indicates that RADLY trades on the over-the-counter market, which is less regulated than major exchanges like NYSE or NASDAQ. This tier allows for more flexibility in trading but may come with increased risks related to transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight compared to stocks listed on major exchanges.
- Potential for lower trading volumes leading to increased volatility.
- Higher bid-ask spreads can result in less favorable trading conditions.
- Less availability of comprehensive financial information for due diligence.
- Increased risk of fraud or misrepresentation in OTC markets.
- Verify the company's financial statements and recent performance.
- Review the management team's background and track record.
- Assess the competitive landscape and market position.
- Check for any regulatory issues or legal challenges.
- Monitor news and updates related to the healthcare sector.
- Established company with over a century of operational history.
- Strong brand recognition in the Brazilian market.
- Transparent financial reporting and disclosures available.
- Active engagement with investors and stakeholders.
- Reputation for quality and customer service in the retail sector.
Common Questions About RADLY (Healthcare)
What does Raia Drogasil S.A. do?
Raia Drogasil S.A. is a leading Brazilian retail pharmacy chain that sells a wide range of products, including prescription and over-the-counter medications, personal care items, cosmetics, and specialty medicines. With over 2,500 stores across Brazil, the company aims to provide accessible healthcare solutions to consumers, leveraging both physical stores and e-commerce platforms.
What do analysts say about RADLY stock?
Analysts generally view RADLY as a stable investment within the healthcare sector, citing its strong market presence and consistent revenue growth. Key valuation metrics, such as a P/E ratio of 21.1 and a profit margin of 2.9%, indicate a solid financial position. Analysts highlight the company's ongoing expansion and product diversification as significant growth drivers.
What are the main risks for RADLY?
Raia Drogasil faces several risks, including potential regulatory changes that could affect the pharmaceutical retail landscape. Additionally, the company contends with intense competition from other pharmacy chains, which could pressure margins. Economic fluctuations may impact consumer spending on healthcare products, while supply chain disruptions could affect product availability in stores.
What are the key factors to evaluate for RADLY?
Raia Drogasil S.A. (RADLY) holds an AI score of 49/100 (low). P/E: 21.1x vs the S&P 500's ~20-25x. Analysts target $5.40 (+53%). Not financial advice.
How frequently does RADLY data refresh on this page?
RADLY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RADLY's recent stock price performance?
Raia Drogasil S.A. (RADLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market presence with over 2,500 stores. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RADLY overvalued or undervalued right now?
Raia Drogasil S.A. (RADLY) trades at 21.1x earnings. Analysts target $5.40 (+53%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RADLY?
Before investing in Raia Drogasil S.A. (RADLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information; financial metrics are subject to change based on market conditions.